Display options
Cite
Najafi A, Pourfarzam M, Zadhoush F. Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome. J Res Med Sci. 2021;26:6doi: 10.4103/jrms.JRMS_249_20.
Najafi, A., Pourfarzam, M., & Zadhoush, F. (2021). Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 266. https://doi.org/10.4103/jrms.JRMS_249_20
Najafi, Ali, et al. "Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 26 (2021): 6. doi: https://doi.org/10.4103/jrms.JRMS_249_20
Najafi A, Pourfarzam M, Zadhoush F. Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome. J Res Med Sci. 2021 Jan 28;26:6. doi: 10.4103/jrms.JRMS_249_20. eCollection 2021. PMID: 34084185; PMCID: PMC8103957.
Copy Download .nbib Format: NLM
Share it on

J Res Med Sci. 2021 Jan 28;26:6. doi: 10.4103/jrms.JRMS_249_20. eCollection 2021.

Oxidant/antioxidant status in Type-2 diabetes mellitus patients with metabolic syndrome.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Ali Najafi, Morteza Pourfarzam, Fouzieh Zadhoush

Affiliations

  1. Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

PMID: 34084185 PMCID: PMC8103957 DOI: 10.4103/jrms.JRMS_249_20

Abstract

BACKGROUND: The concurrence of metabolic syndrome (MS) and diabetes mellitus (DM) is increasing worldwide. The long-term complications of these chronic diseases are a threat to patients' well-being. Oxidative stress is involved in the pathogenesis of several diseases. To understand the basic pathophysiological mechanisms of Type-2 DM (T2DM) and its related complications, we aimed to investigate the oxidant/antioxidant status and Na

MATERIALS AND METHODS: A population of ninety individuals including fifty patients diagnosed with T2DM and MS, but without overt diabetes complications, and forty individuals without T2DM or MS as control group participated in this study. Plasma malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) activities, total antioxidant capacity (TAC), and Na

RESULTS: Plasma MDA in patients group was statistically significantly higher than that of controls (

CONCLUSION: Because T2DM patients were without any vascular complications, antioxidant defense results may reflect the lack of progression of diabetes complications in these patients. These results emphasize the need for initial and continued assessment of cardiovascular disease risks in diabetic individuals. Implementation of timely interventions may improve the management of diabetes and prevent the progression of diabetes complications.

Copyright: © 2021 Journal of Research in Medical Sciences.

Keywords: Diabetes mellitus Type 2; metabolic syndrome; oxidative stress; sodium-potassium-exchanging ATPase

Conflict of interest statement

There are no conflicts of interest.

References

  1. Am J Hypertens. 2006 Jun;19(6):587-92 - PubMed
  2. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49 - PubMed
  3. Anal Biochem. 1978 Jun 15;87(1):206-10 - PubMed
  4. Niger J Clin Pract. 2016 Jan-Feb;19(1):128-32 - PubMed
  5. Coron Artery Dis. 2015 May;26(3):239-44 - PubMed
  6. Oxid Med Cell Longev. 2017;2017:6501046 - PubMed
  7. Diabetes Res Clin Pract. 2006 Sep;73(3):284-91 - PubMed
  8. Adv Biomed Res. 2016 Sep 26;5:153 - PubMed
  9. Redox Biol. 2017 Oct;13:94-162 - PubMed
  10. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  11. Oxid Med Cell Longev. 2019 May 12;2019:5953685 - PubMed
  12. Eur J Clin Invest. 2008 Jul;38(7):510-5 - PubMed
  13. J Clin Invest. 2004 Dec;114(12):1752-61 - PubMed
  14. Free Radic Biol Med. 2000 Dec;29(11):1122-8 - PubMed
  15. Diabetes Care. 2013 May;36(5):1341-6 - PubMed
  16. Curr Hypertens Rep. 2006 Jun;8(3):191-8 - PubMed
  17. J Res Med Sci. 2020 Apr 13;25:43 - PubMed
  18. Biofactors. 2019 Jan;45(1):35-42 - PubMed
  19. J Res Med Sci. 2015 Aug;20(8):763-70 - PubMed
  20. JAMA. 2004 Sep 22;292(12):1440-6 - PubMed
  21. J Res Med Sci. 2019 Dec 23;24:108 - PubMed
  22. Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28 - PubMed
  23. Vascul Pharmacol. 2018 Jan;100:1-19 - PubMed
  24. Pak J Pharm Sci. 2005 Apr;18(2):6-10 - PubMed
  25. J Clin Invest. 2013 Jul;123(7):2764-72 - PubMed
  26. Am J Physiol Cell Physiol. 2019 Sep 1;317(3):C420-C433 - PubMed
  27. Mol Cell Endocrinol. 2010 May 14;320(1-2):25-33 - PubMed

Publication Types